Bariatric Surgery CandidatePhase 2NCT07515391
Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery
A Phase 2 study testing Dapagliflozin 10 MG in people with Bariatric Surgery Candidate and Type2 Diabetes, run by Dasman Diabetes Institute at 1 site in Kuwait.
Trial summary
This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes. Read more about this study
- Who is it for?
- Ages 21 to 70 years
- Conditions the study is for
- Bariatric Surgery Candidate, Type2 Diabetes
- What is being tested?
- Dapagliflozin 10 MG
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteKuwait
- Study dates
- 22 Oct 2019to 22 Oct 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- People diagnosed with type 2 diabetes prior to bariatric surgery.
- People did not have diabetes prior to bariatric surgery.
- Willing to participate in this study.
Who cannot join
- Type 1 diabetes
- Secondary diabetes
- History of ketoacidosis
- History of pancreatitis and pancreatectomy.
- History of primary renal glycosuria or hereditary glucose-galactose malabsorption.
- Active diabetes complications, nephropathy (dipstick positive proteinuria, or reduced eGFR (<60 ml/min), proliferative retinopathy.
Show all 16Show fewer
- Clinically significant abnormal liver function test.
- Pregnant ladies, or intending pregnancy or breastfeeding.
- Patients using insulin therapy or a sulfonylurea.
- Uncontrolled hypertension.
- Uncontrolled thyroid disease.
- Any history of serious hypertension reaction to the dapagliflozin or SGLT-2 inhibitor.
- History of malignancy within 5-year of screening.
- Presence of any other medical condition that would in the opinion of the investigator, preclude safe participation in the study.
- HbA1c >10.5
- Unable to sign the consent form.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.
Read the detailed description
Dapagliflozin is a highly selective sodium-glucose transporter 2 (SGLT2) inhibitor, an approved drug for the treatment of type 2 diabetes. It leads to urinary glucose excretion and a reduction of weight. This results in a reduction of both fasting and postprandial glucose levels. This is reported that the treatment of type 2 diabetes with dapagliflozin carries a low risk of hypoglycaemia and have a beneficial effect on weight and blood pressure.
This study hypothesized that bariatric surgery is effective for weight loss. But some patients experience large changes in the blood glucose after meals that lead to hyper and hypoglycaemia and weight regain. This study propose that the use of SGLT-2 inhibitors, which lower glucose and body weight by promoting its renal excretion, will reduce glucose variability in patients after bariatric surgery.
- Conditions
- Bariatric Surgery Candidate, Type2 Diabetes
- Being tested
- Dapagliflozin 10 MG
- Keywords
- SGLT-2, Bariatric Surgery, Type 2 diabetes, Glucose variability
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dapagliflozin 10 MGDrug
Dapagliflozin 10 mg drug will be administered in both arms for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| (1) People with type 2 diabetes with post-bariatric surgery | Active comparator | Not described Receives: Drug: Dapagliflozin 10 MG |
| (2) people without diabetes with post-bariatric surgery. | Active comparator | Not described Receives: Drug: Dapagliflozin 10 MG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time spent below 3 mmol/L and above 10 mmol/L on and off dapagliflozin
Time spent below 3 mmol/L and above 10 mmol/L on and off dapagliflozin
Measured: 12 weeks
Secondary outcomes (4)
Glucose variability, glycemic control (HbA1c)
Glucose variability, glycemic control (HbA1c)
Measured: 12 weeks
Glycemic control (HbA1c)
Glycemic control (HbA1c)
Measured: 12 weeks
change in body weight (Kg)
change in body weight (Kg)
Measured: 12 weeks
change in insulin resistance and beta cell function (HOMA-IR and HOMA-S)
change in insulin resistance and beta cell function (HOMA-IR and HOMA-S)
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2026
- Study start22 Oct 2019
- Primary completion1 May 2021
- Study completion22 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bariatric Surgery CandidateStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study has two groups (1) People with type 2 diabetes with post-bariatric surgery, (2) people without diabetes with post-bariatric surgery.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dasman Diabetes Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Kuwait Foundation for the Advancement of Sciences
- Responsible party
- Principal investigator, Dr. Ebaa Al Ozairi, Dasman Diabetes Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07515391
- Sponsor's protocol ID
- RA HM 2019-023
- Status last verified
- Mar 2026
- First submitted
- 11 Dec 2019
- Last updated
- 7 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery
- ClinicalTrials.gov ID
- NCT07515391
- Acronym / sponsor ID
- RA HM 2019-023
- Conditions
- Bariatric Surgery Candidate, Type2 Diabetes
- Keywords
- SGLT-2, Bariatric Surgery, Type 2 diabetes, Glucose variability
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Dasman Diabetes InstituteUniversity, hospital or other
- Collaborators
- Kuwait Foundation for the Advancement of Sciences
- Study start
- 22 Oct 2019 (actual)
- Primary completion
- 1 May 2021 (actual)
- Study completion
- 22 Oct 2026 (estimated)
- First posted
- 7 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.
Detailed description
Dapagliflozin is a highly selective sodium-glucose transporter 2 (SGLT2) inhibitor, an approved drug for the treatment of type 2 diabetes. It leads to urinary glucose excretion and a reduction of weight. This results in a reduction of both fasting and postprandial glucose levels. This is reported that the treatment of type 2 diabetes with dapagliflozin carries a low risk of hypoglycaemia and have a beneficial effect on weight and blood pressure.
This study hypothesized that bariatric surgery is effective for weight loss. But some patients experience large changes in the blood glucose after meals that lead to hyper and hypoglycaemia and weight regain. This study propose that the use of SGLT-2 inhibitors, which lower glucose and body weight by promoting its renal excretion, will reduce glucose variability in patients after bariatric surgery.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- This study has two groups (1) People with type 2 diabetes with post-bariatric surgery, (2) people without diabetes with post-bariatric surgery.
| Arm | Type | Receives |
|---|---|---|
| (1) People with type 2 diabetes with post-bariatric surgery | Active comparator | Drug: Dapagliflozin 10 MG |
| (2) people without diabetes with post-bariatric surgery. | Active comparator | Drug: Dapagliflozin 10 MG |
Who may qualify
- Ages
- 21 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- People diagnosed with type 2 diabetes prior to bariatric surgery.
- People did not have diabetes prior to bariatric surgery.
- Willing to participate in this study.
Key exclusion criteria (16 listed)
- Type 1 diabetes
- Secondary diabetes
- History of ketoacidosis
- History of pancreatitis and pancreatectomy.
- History of primary renal glycosuria or hereditary glucose-galactose malabsorption.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dapagliflozin 10 MGDapagliflozin 10 mg drug will be administered in both arms for 12 weeks. | Drug | (1) People with type 2 diabetes with post-bariatric surgery, (2) people without diabetes with post-bariatric surgery. |
Primary outcome
Time spent below 3 mmol/L and above 10 mmol/L on and off dapagliflozin
Time frame: 12 weeks
Time spent below 3 mmol/L and above 10 mmol/L on and off dapagliflozin
4 secondary outcomes
Glucose variability, glycemic control (HbA1c)
Time frame: 12 weeks
Glycemic control (HbA1c)
Time frame: 12 weeks
change in body weight (Kg)
Time frame: 12 weeks
change in insulin resistance and beta cell function (HOMA-IR and HOMA-S)
Time frame: 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Bariatric Surgery Candidate
Active, not recruiting
Comparing 150cm OAGB With 150cm Biliopancreatic Limb RYGB. A Non-inferiority Trial
Bariatric Surgery Candidate, Obesity
Active, not recruiting
Stepwise PEEP vs Sustained Inflation in Bariatric Surgery Patients
Recruitment, Bariatric Surgery Candidate
RecruitingObservational study
Blood Collection Biorepository for Liver Disease Research
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C
Enrolling by invitationObservational study
Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome
Obese, Healthy
Active, not recruiting
Evaluation of the Stress Response in Bariatric Surgery With and Without the Use of Opioids
Opioid Use, Unspecified, Bariatric Surgery Candidate
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Dapagliflozin 10 MG in people with Bariatric Surgery Candidate and Type2 Diabetes, run by Dasman Diabetes Institute at 1 site in Kuwait.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Kuwait. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time spent below 3 mmol/L and above 10 mmol/L on and off dapagliflozin (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.